In a developing legal story this week, the Federal Circuit has chosen to stand by the decision previously made by the patent board – atomic ruling that declared there to be nothing patentable about a new approach to administering a well-known pulmonary hypertension drug. This decision could pave the way to some unsettling times for United Therapeutics, as it threatens their recent legal victory over a generic in Delaware’s federal court.
For those who have been closely tracking the case, the Federal Circuit’s stance is noteworthy. It maintains that the purportedly innovative method of administering the drug is not novel enough to warrant a patent, thus potentially altering the landscape of operations for United Therapeutics.
Considering the overall implications, this turn of events brings forth an interesting conversation about the bounds of patentability in the pharmaceutical industry. In particular, the courts’ interpretation of what constitutes a novel administration method for existing drugs – a highly relevant topic for corporations and law firms specialising in patent law.
Further details of the case and its potential future trajectory still remain to be fully unveiled. Those interested in delving deeper into the matter can obtain additional insights from the original report on Law360.